DEFA14A: ESSA Pharma Amends Merger Terms, Lowers Upfront Cash

ESSA Pharma Inc. has amended its business combination agreement, reducing the immediate cash payout to shareholders while increasing the contingent value rights due to a Nasdaq trading issue.

Summary

• ESSA Pharma Inc. has filed definitive additional materials to amend and supplement its definitive proxy statement for a special meeting on October 3, 2025.
• The amendment revises the terms of the business combination agreement with XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation.
• Shareholders are now expected to receive approximately US$0.12 per Common Share at closing, a significant reduction from the previously stated US$1.91.
• The contingent value right (CVR) component has increased, now representing the right to receive up to approximately US$0.14 per CVR.
• CVR proceeds are structured to cover: US$3,800,000 for Company Litigation, US$3,500,000 for Potential Contingent Claim Liability, and US$150,000 for Legacy Liability, less up to US$750,000 to be retained by the Purchaser.
• The Contingent Reserve in the agreement has been increased from US$3,700,000 to US$7,450,000.
• Target Closing Net Cash has been decreased from US$90,000,000 to US$85,250,000, accounting for an additional US$1,000,000 in potential company costs.
• The changes were primarily driven by a 'Due Bill Matter' related to a typo in a prior press release (August 14, 2025) concerning the due bill trading period, which led to a Nasdaq trading halt on August 25, 2025, and potential contingent claims.
• The Special Meeting of Securityholders, originally scheduled for September 10, 2025, and then adjourned to September 29, 2025, is now confirmed for October 3, 2025.
• Leerink Partners, the financial advisor, was not requested to, and did not, render an opinion on the fairness of the financial terms as modified by this amendment.

Sentiment

Score: 3

Explanation: The significant reduction in upfront cash consideration and the increased reliance on contingent value rights, coupled with the lack of an updated fairness opinion for the revised terms, indicate a less favorable outcome for shareholders. The underlying 'Due Bill Matter' also points to operational issues.

Positives

• The Board and Transaction Committee unanimously approved the amendment, believing it to be in the best interests of the Company and its Shareholders, considering the risks and costs of not closing the transaction versus pursuing liquidation.
• The amendment provides a structured way to allocate risks for potential contingent liabilities arising from the 'Due Bill Matter'.
• The CVR structure offers shareholders an opportunity to receive additional consideration based on the resolution of litigation and other liabilities, albeit with uncertainty.

Negatives

• The immediate cash consideration per common share for shareholders has significantly decreased from approximately US$1.91 to an estimated US$0.12.
• A substantial portion of the consideration (up to US$0.14 per CVR) is now contingent and subject to the resolution of various litigation and liabilities, introducing uncertainty and delayed payment.
• Leerink Partners did not provide a fairness opinion on the financial terms as modified by the amendment, which could raise concerns about the revised valuation for shareholders.
• The 'Due Bill Matter' and associated potential contingent claim liability indicate operational or disclosure issues that led to renegotiation of the merger terms.
• The increase in the Contingent Reserve from US$3,700,000 to US$7,450,000 and decrease in Target Closing Net Cash from US$90,000,000 to US$85,250,000 suggest a less favorable financial position for the company at closing.

Risks

• Holders of CVRs may never receive any proceeds if Company Litigation Expenses and Potential Contingent Claim Liability Expenses exceed the allocated amounts (US$3,800,000 and US$3,500,000 respectively, plus the US$150,000 for Legacy Liability, less the US$750,000 CVR Retention Amount).
• The Purchaser and the Company may be targets of legal claims, securities class action, derivative lawsuits, and other claims, including those related to the Potential Contingent Claim Liability, which could result in substantial costs and divert management time.
• Injunctions from lawsuits could delay or prevent the Arrangement from being completed.
• The date of the Special Meeting could change again.
• Disruptions from the transaction could harm the Company's business, plans, and operations.
• The Company's ability to retain and hire key personnel may be impacted.
• Potential adverse reactions or changes to business relationships could result from the announcement or completion of the transaction.
• Continued availability of capital and financing and rating agency actions are risks.
• Legislative, regulatory, and economic developments could affect the Company's business.
• The accuracy of the Company's financial projections is a risk.
• General business, market, and economic conditions pose risks.
• Certain restrictions during the pendency of the transaction may impact the Company's ability to pursue business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events (terrorism, pandemics, war) are risks.
• Significant transaction costs associated with the Arrangement.
• The transaction may be more expensive to complete than anticipated due to unexpected factors.
• Competitive responses to the transaction.

Future Outlook

The company anticipates the completion of the transaction on the revised terms, subject to securityholder, regulatory, and court approvals. The CVRs offer a potential future payout to shareholders, contingent on the resolution of various legal and financial liabilities within specified timeframes. The company acknowledges the speculative nature of CVR payments and that there is no assurance holders will receive any payments.

Management Comments

• Under the Amendment, based on the estimates of ESSA’s management, ESSA shareholders are expected to receive approximately US$0.12 per Common Share at closing plus one non-transferable contingent value right (CVR) per Common Share, which now represents the right to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the Transaction as described herein.
• The Board considered the inclusion of the proposed Potential Contingent Claim Liability and believed the Amendment was a fair and equitable way to allocate risks for such contingent liabilities as a result of the Due Bill Matter.
• The Board considered the risks and costs of not closing the Transaction, including the time value of money and costs and risks of pursuing a liquidation, including that the Potential Contingent Claim Liability Expenses would continue to exist in a liquidation. The Board also considered the costs of proceeding with the Transaction, such as the additional costs of retaining management and continuing as a public company and believed the Amendment was in the best interest of the Shareholders.

Industry Context

The filing does not provide specific industry context or comparisons to competitors. It focuses solely on the company's specific merger amendment and the reasons behind it.

Management Changes

Corporate Governance

Legal Proceedings

• Company Litigation: Any proceeding against or involving the Company and its directors/officers existing as of the date of the original agreement or arising within 18 months following closing, from facts/circumstances existing at Effective Time (excluding Potential Contingent Claim Liability).
• Potential Contingent Claim Liability: Any proceeding against or involving the Company and its directors/officers arising from the Company's public disclosures on August 14, 2025, and August 25, 2025, regarding the due bill trading period on Nasdaq.
• The filing mentions the possibility of 'securities class action and derivative lawsuits' against the Purchaser or the Company, which could result in substantial costs and delay the Arrangement.

Related Party Transactions

• David Parkinson, a Board member, declared he would be receiving a 'collateral Benefit in the Transaction within the meaning of Multilateral Instrument 61-101' and recused himself from the Board meeting approving the amendment. This indicates a disclosed related party benefit.

Stakeholder Impact

• Shareholders: Will receive significantly less upfront cash (US$0.12 vs. US$1.91) and a larger portion of consideration as contingent value rights (CVRs), introducing uncertainty and delayed payments. The value of CVRs is speculative.
• Company (ESSA Pharma): Faces ongoing litigation risks (Company Litigation, Potential Contingent Claim Liability) which will be covered by the CVR structure, potentially reducing its post-acquisition liabilities.
• Purchaser (Xeno Acquisition Corp.): Has negotiated a lower upfront cash payment and shifted more risk to contingent payments, potentially improving its immediate cash outlay for the acquisition.
• Directors/Officers: Face potential legal proceedings (Company Litigation, Potential Contingent Claim Liability) but the CVR structure is designed to cover associated expenses and damages.

Next Steps

• Securityholders to consider and vote on the Arrangement Resolution, advisory compensation, and (if Arrangement fails) voluntary liquidation and dissolution at the Special Meeting on October 3, 2025.
• ESSA intends to apply to the British Columbia Supreme Court for an order varying the Interim Order, including setting the meeting date, dissent rights deadline (October 1, 2025), and Final Order hearing date (October 7, 2025).
• Parent and Purchaser to deposit CVR Payment Amounts with the Rights Agent for payment to Holders upon final determination of Final Company Net Cash or resolution of Company Litigation/Potential Contingent Claim Liability.
• CVR Committee to control the defense of Company Litigation and Potential Contingent Claim Liability (subject to certain conditions).

Key Dates

Recommendation

The significant reduction in immediate cash consideration for shareholders (from US$1.91 to an estimated US$0.12 per share) and the increased reliance on speculative contingent value rights (CVRs) make this transaction less attractive. The CVRs are subject to the uncertain outcomes of litigation and other liabilities, with no guarantee of payment. The fact that Leerink Partners did not provide a fairness opinion on the *amended* financial terms further diminishes confidence in the revised deal's value for shareholders. Given the reduced certainty and lower upfront value, selling shares to avoid the contingent risks and capture any remaining market value before the transaction closes would be a prudent move for a seasoned investor.

Keywords

ESSA Pharma, XenoTherapeutics, XOMA Royalty Corporation, Business Combination Agreement, Merger Amendment, Contingent Value Rights, CVR, SEC Filing, Proxy Statement, Shareholder Meeting, Due Bill Matter, Litigation Risk, Acquisition, Financial Reporting